Kymera Therapeutics’ (KYMR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report released on Friday, Benzinga reports. They currently have a $46.00 price target on the stock. A number of other research firms have also recently issued reports on KYMR. Oppenheimer dropped their price objective on Kymera Therapeutics […]
More Stories
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns “Buy” Rating from Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on...
Calumet Specialty Products Partners (NASDAQ:CLMT) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of Calumet Specialty Products Partners (NASDAQ:CLMT – Free Report) to a sell rating in a research report...
Pure Cycle (NASDAQ:PCYO) Upgraded at StockNews.com
StockNews.com upgraded shares of Pure Cycle (NASDAQ:PCYO – Free Report) from a sell rating to a buy rating in a...
HP Inc. (NYSE:HPQ) Shares Acquired by Swiss National Bank
Swiss National Bank lifted its holdings in shares of HP Inc. (NYSE:HPQ – Free Report) by 0.3% in the 3rd...
Swiss National Bank Grows Holdings in Old Dominion Freight Line, Inc. (NASDAQ:ODFL)
Swiss National Bank grew its holdings in Old Dominion Freight Line, Inc. (NASDAQ:ODFL – Free Report) by 0.1% during the...
Swiss National Bank Buys 25,000 Shares of PG&E Co. (NYSE:PCG)
Swiss National Bank lifted its stake in PG&E Co. (NYSE:PCG – Free Report) by 0.4% during the 3rd quarter, according...